Edgewise Reports Positive Phase 2 Results for Heart Condition Drug
Patients with obstructive and nonobstructive hypertrophic cardiomyopathy showed significant clinical improvement in a 12-week trial of EDG-7500, with no evidence of the systolic function decline that often complicates existing heart therapies. The findings pave the way for the company to launch a Phase 3 study later next year.























